US960914A - Pills for the treatment of diabetes mellitus. - Google Patents
Pills for the treatment of diabetes mellitus. Download PDFInfo
- Publication number
- US960914A US960914A US51884009A US1909518840A US960914A US 960914 A US960914 A US 960914A US 51884009 A US51884009 A US 51884009A US 1909518840 A US1909518840 A US 1909518840A US 960914 A US960914 A US 960914A
- Authority
- US
- United States
- Prior art keywords
- pills
- diabetes mellitus
- blood
- treatment
- enzymes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Definitions
- Diabetes mellitus is a chronic disease of metabolism in which the carbohydrates contained in the food and drink taken by the sufferer are converted into glucose and pass into the urine without contributing to the depend upon the blood for their proper functions it necessarily follows that if the blood can not supply the proper nourishment to said parts the latter will become defective and the blood become charged with abnormal or poisonous matter.
- the blood like every other organic matter of vegetable or animal origin, contains enzymes which perform the necessary chemical changes.
- the blood of the sufferer is not of the proper composition and does not contain either the right or suflicient quantity of enzymes to properly oxidize and assimilate the carbohydrates.
- my invention substitute for the natural enzymes, which should be present in the blood, vegetable enzymes,- the socalled oxydases and peroxydaseswhich under certain conditions split up and oxidize the glucose, the products of which are then utilized for the nourishment of the body. But as these enzymes only act in a weak acid or neutral solution and still bet ter in an alkaline solution, and the acid condition of the blood of a diabetic patient is such as to destroy the function,-namely the possibility of utilizing sugar-of even the natural blood enzymes it is necessary to diminish or remove the acidity of the blood. For this Ipurpose I mix the vegetable enzymes wit finely pulverized alkaline salts.
- the vegetable enzymes and alkaline salts are then formed into pills and coated with keratin or the like, so as to prevent the acids present in the stomach from either reducing or totally annulling the effect of the alkaline enzyme mixture.
- the pill passes unchanged into the duodenum where it is dissolved by the alkaline liquid present in the intestine. It is then absorbed and passes into the blood, the abnormal amount of acid in the latter being neutralized, so that the natural enzymes of the blood as well as the artificially addedenzymes are able to work under physiological conditions and split up and oxidize the sugar compounds, thus enabling the latter to contribute to the nourishment of the body.
- the leaves, roots or other parts of the plant are inacerated, either with-or without the addition of water, and then if required slightly fermented.
- the liquid so obtained which contains the enzyme in solution is thenfiltered. and the enzyme successively preci itated and purified by alcohol, ether or ot er suitable means.
- This constituent is like the corresponding constituent found in yeast and is now known by the same name viz. zymase.
- the precipitated enzyme or the liquid zymase as the case may be,
- the pills are then mixed with the necessary proportion of alkaline salts and formed mto pills, which are then coated with keratin or other substance incapable of being dissolved by the gastric julce present in the stomach.
- the pills can be provided with a second coating of such nature as to make them palatable.
- a suitable quantity of common sugar beets such for example as 10 kilos is thoroughly cleaned, reduced to a pulp and then subjected to a pressure of, say, 300 atmospheres by means of a suitable hydraulic press.
- the liquid obtained by this operation about 7 liters, is then poured into a vessel and mixed with 700 c. c. m. of alcohol of 96% purity, so as to precipitate the sugar and mucous substance contained in the mixture.
- the liquid in said vessel is removed and filtered, and 45 liters of absolute alcohol added to the filtrate.
- the resultant precipitate is filtered and Washed with a little absolute alcohol and then placed in a closed vessel.
- the alcohol is then evaporated preferably at a temperature of about 20 to 30 C. by the withdrawal, by any suitable apparatus, of the air contained in said vessel.
- the dry powder resulting from the last step which weighs about 20 grams, is then mixed with 20 grams of magnesium peroxid, 20 ams of lithium carbonate, and 4.8 grams 0 magnesium oxid. This mixture will be sufiicient to form 400 pills or tablets of 0.162 gram, or 24,; grains, each.
- Pills for the treatment of diabetes mellitus containing a compressed mixture of oxydases and an alkaline salt provided with a coating consistin of a substance insoluble by the gastric juices of the stomach, substantially as described.
- Pills for the treatment of diabetes mellitus containing a compressed mixture of oxydases of the genus beta and an alkaline salt provided with a coating of' keratin, substantially as described.
Description
I liolfirawing.
ARTHUR HEINEMANN, OF LONDON, ENGLAND.
PIL LS FOR THE TREATMENT OF DIABETES MELLITUS.
Specification of Letters Patent.
Application filed September 21, 1909. Serial No. 518,840.
Patented June '7, 1910.
To all whom it'may concern: 7
Be it known that I, ARTHUR HEINEMANN, a subject of the Emperor of Germany, residing at Carlton Mansions, Portsdown Road, Maida Vale, London, W., England, have invented new and useful Improvements in Pills for the Treatment of Diabetes Mellitus, of which the following is a specification.
Diabetes mellitus is a chronic disease of metabolism in which the carbohydrates contained in the food and drink taken by the sufferer are converted into glucose and pass into the urine without contributing to the depend upon the blood for their proper functions it necessarily follows that if the blood can not supply the proper nourishment to said parts the latter will become defective and the blood become charged with abnormal or poisonous matter.
To combat a disease it is necessary to remove its cause. This is effected by the introduction into the blood of a particular substance which in the case of diabetes mellitus must be such as will enable the blood to regain its ability to split up and oxidize the glucose.
The blood, like every other organic matter of vegetable or animal origin, contains enzymes which perform the necessary chemical changes. In the case of diabetes mellitus the blood of the sufferer is not of the proper composition and does not contain either the right or suflicient quantity of enzymes to properly oxidize and assimilate the carbohydrates.
According to my invention I substitute for the natural enzymes, which should be present in the blood, vegetable enzymes,- the socalled oxydases and peroxydaseswhich under certain conditions split up and oxidize the glucose, the products of which are then utilized for the nourishment of the body. But as these enzymes only act in a weak acid or neutral solution and still bet ter in an alkaline solution, and the acid condition of the blood of a diabetic patient is such as to destroy the function,-namely the possibility of utilizing sugar-of even the natural blood enzymes it is necessary to diminish or remove the acidity of the blood. For this Ipurpose I mix the vegetable enzymes wit finely pulverized alkaline salts. The vegetable enzymes and alkaline salts are then formed into pills and coated with keratin or the like, so as to prevent the acids present in the stomach from either reducing or totally annulling the effect of the alkaline enzyme mixture. The pill passes unchanged into the duodenum where it is dissolved by the alkaline liquid present in the intestine. It is then absorbed and passes into the blood, the abnormal amount of acid in the latter being neutralized, so that the natural enzymes of the blood as well as the artificially addedenzymes are able to work under physiological conditions and split up and oxidize the sugar compounds, thus enabling the latter to contribute to the nourishment of the body.
Experience has shown that nearly all vegetable enzymes having an oxidizing effect u on the carbohydrates are useful for the a ove named purpose, especially the oxydases and peroxydases of the genera cucurbita, cochlearia and beta. As regards the alkaline salts to be used those readily absorbed in the intestine such, for instance, as the carbonates of lithium, sodium, potassium and magnesium, and the oxid and peroxid of magnesium should .be employed. Since a peroxydase only acts in the presence of peroxld compounds, it is necessary to always use a peroxld, for example dioxid of magnesium with the peroxydases. The enzyme is prepared from the plant in any suitable or well known manner, such as the following. The leaves, roots or other parts of the plant are inacerated, either with-or without the addition of water, and then if required slightly fermented. The liquid so obtained which contains the enzyme in solution is thenfiltered. and the enzyme successively preci itated and purified by alcohol, ether or ot er suitable means. This constituent is like the corresponding constituent found in yeast and is now known by the same name viz. zymase. The precipitated enzyme or the liquid zymase, as the case may be,
is then mixed with the necessary proportion of alkaline salts and formed mto pills, which are then coated with keratin or other substance incapable of being dissolved by the gastric julce present in the stomach. The pills can be provided with a second coating of such nature as to make them palatable.
In the case of the genus beta the invention could be carried out in the following manner: A suitable quantity of common sugar beets, such for example as 10 kilos is thoroughly cleaned, reduced to a pulp and then subjected to a pressure of, say, 300 atmospheres by means of a suitable hydraulic press. The liquid obtained by this operation, about 7 liters, is then poured into a vessel and mixed with 700 c. c. m. of alcohol of 96% purity, so as to precipitate the sugar and mucous substance contained in the mixture. The liquid in said vessel is removed and filtered, and 45 liters of absolute alcohol added to the filtrate. The resultant precipitate is filtered and Washed with a little absolute alcohol and then placed in a closed vessel. The alcohol is then evaporated preferably at a temperature of about 20 to 30 C. by the withdrawal, by any suitable apparatus, of the air contained in said vessel. The dry powder resulting from the last step, which weighs about 20 grams, is then mixed with 20 grams of magnesium peroxid, 20 ams of lithium carbonate, and 4.8 grams 0 magnesium oxid. This mixture will be sufiicient to form 400 pills or tablets of 0.162 gram, or 24,; grains, each.
I WlSh it to be understood that although I have in the fore oin description advisedly used the wor il it is obvious that the mixture of vegeta le enzymes and alkaline salts may be pressed into the form of small tablets.
Having described my invention, what- I claim and desire to secure by Letters Patent is 1. Pills for the treatment of diabetes mellitus containing a compressed mixture of oxydases and an alkaline salt provided with a coating consistin of a substance insoluble by the gastric juices of the stomach, substantially as described.
2. Pills for the treatment of diabetes mellitus containing a compressed mixture of oxydases of the genus beta and an alkaline salt provided with a coating of' keratin, substantially as described.
,In testimony whereof I have signed my name to this specification in the presence of two subscribing witnesses.
ARTHUR HEINEMANN.
Witnesses: ARTHUR F. ENNIS, F. L. BANDS.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51884009A US960914A (en) | 1909-09-21 | 1909-09-21 | Pills for the treatment of diabetes mellitus. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51884009A US960914A (en) | 1909-09-21 | 1909-09-21 | Pills for the treatment of diabetes mellitus. |
Publications (1)
Publication Number | Publication Date |
---|---|
US960914A true US960914A (en) | 1910-06-07 |
Family
ID=3029312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US51884009A Expired - Lifetime US960914A (en) | 1909-09-21 | 1909-09-21 | Pills for the treatment of diabetes mellitus. |
Country Status (1)
Country | Link |
---|---|
US (1) | US960914A (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030119089A1 (en) * | 2001-09-25 | 2003-06-26 | Dyke Mark Van | Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same |
US20030219486A1 (en) * | 2002-04-10 | 2003-11-27 | Van Dyke Mark E. | Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks |
US20030224052A1 (en) * | 2002-04-22 | 2003-12-04 | Van Dyke Mark E. | Hydrogel with controllable merchanical, chemical, and biological properties and method for making same |
US20030228353A1 (en) * | 2002-01-28 | 2003-12-11 | Keraplast Technologies, Ltd. | Bioactive keratin peptides |
US20040120910A1 (en) * | 2002-04-10 | 2004-06-24 | Dyke Mark Van | Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks |
US6783546B2 (en) | 1999-09-13 | 2004-08-31 | Keraplast Technologies, Ltd. | Implantable prosthetic or tissue expanding device |
US6849092B2 (en) | 1999-09-13 | 2005-02-01 | Keraplast Technologies, Ltd. | Implantable prosthetic or tissue expanding device |
US20050058686A1 (en) * | 2002-07-25 | 2005-03-17 | Mark Van Dyke | Bioactive coating for medical devices |
US6989437B2 (en) | 2002-04-10 | 2006-01-24 | Keraplast Technologies, Ltd. | Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks |
US20070166348A1 (en) * | 2005-10-21 | 2007-07-19 | Van Dyke Mark E | Keratin bioceramic compositions |
US20080089930A1 (en) * | 1999-09-13 | 2008-04-17 | Keraplast Technologies, Ltd. | Keratin-Based Powders and Hydrogel for Pharmaceutical Applications |
US20090004242A1 (en) * | 2006-02-17 | 2009-01-01 | Van Dyke Mark E | Coatings and Biomedical Implants Formed From Keratin Biomaterials |
US20110137329A1 (en) * | 2006-02-10 | 2011-06-09 | Dyke Mark E Van | Nerve regeneration employing keratin biomaterials |
US20110217356A1 (en) * | 2010-03-05 | 2011-09-08 | Van Dyke Mark E | Controlled delivery system |
US20110217285A1 (en) * | 2010-03-08 | 2011-09-08 | Van Dyke Mark E | Keratin biomaterials for treatment of ischemia |
US8258093B2 (en) | 2006-02-17 | 2012-09-04 | Wake Forest University Health Sciences | Wound healing compositions containing keratin biomaterials |
US8637231B2 (en) | 2004-08-17 | 2014-01-28 | Wake Forest University Health Sciences | Method for increasing the volume of a blood substitute with an expander comprising basic alpha keratose |
US9068162B2 (en) | 2007-08-17 | 2015-06-30 | Wake Forest University Health Sciences | Keratin biomaterials for cell culture and methods of use |
US9220754B2 (en) | 2010-11-17 | 2015-12-29 | Wake Forest University Health Sciences | Keratin compositions for treatment of bone deficiency or injury |
-
1909
- 1909-09-21 US US51884009A patent/US960914A/en not_active Expired - Lifetime
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6849092B2 (en) | 1999-09-13 | 2005-02-01 | Keraplast Technologies, Ltd. | Implantable prosthetic or tissue expanding device |
US20080089930A1 (en) * | 1999-09-13 | 2008-04-17 | Keraplast Technologies, Ltd. | Keratin-Based Powders and Hydrogel for Pharmaceutical Applications |
US20050169963A1 (en) * | 1999-09-13 | 2005-08-04 | Southwest Ressearch Institute | Implantable prosthetic or tissue expanding device |
US6783546B2 (en) | 1999-09-13 | 2004-08-31 | Keraplast Technologies, Ltd. | Implantable prosthetic or tissue expanding device |
US20030119089A1 (en) * | 2001-09-25 | 2003-06-26 | Dyke Mark Van | Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same |
US7001988B2 (en) | 2001-09-25 | 2006-02-21 | Keraplast Technologies, Ltd. | Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same |
US20110070276A1 (en) * | 2002-01-28 | 2011-03-24 | Keraplast Technologies, Ltd. | Bioactive keratin peptides |
US20030228353A1 (en) * | 2002-01-28 | 2003-12-11 | Keraplast Technologies, Ltd. | Bioactive keratin peptides |
US8324346B2 (en) | 2002-01-28 | 2012-12-04 | Keraplast Technologies, Ltd. | Bioactive keratin peptides |
US7501485B2 (en) | 2002-01-28 | 2009-03-10 | Keraplast Technologies, Ltd. | Bioactive keratin peptides |
US20030219486A1 (en) * | 2002-04-10 | 2003-11-27 | Van Dyke Mark E. | Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks |
US6914126B2 (en) | 2002-04-10 | 2005-07-05 | Keraplast Technologies, Ltd. | Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks |
US20040120910A1 (en) * | 2002-04-10 | 2004-06-24 | Dyke Mark Van | Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks |
US6989437B2 (en) | 2002-04-10 | 2006-01-24 | Keraplast Technologies, Ltd. | Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks |
US7001987B2 (en) | 2002-04-22 | 2006-02-21 | Keraplast Technologies, Ltd. | Hydrogel with controllable mechanical, chemical, and biological properties and method for making same |
US20030224052A1 (en) * | 2002-04-22 | 2003-12-04 | Van Dyke Mark E. | Hydrogel with controllable merchanical, chemical, and biological properties and method for making same |
US20050058686A1 (en) * | 2002-07-25 | 2005-03-17 | Mark Van Dyke | Bioactive coating for medical devices |
US20090148488A1 (en) * | 2002-07-25 | 2009-06-11 | Keraplast Technologies, Ltd. | Bioactive coating for medical devices |
US8637231B2 (en) | 2004-08-17 | 2014-01-28 | Wake Forest University Health Sciences | Method for increasing the volume of a blood substitute with an expander comprising basic alpha keratose |
US11173233B2 (en) | 2005-10-21 | 2021-11-16 | Wake Forest University Health Sciences | Keratin bioceramic compositions |
US8920827B2 (en) | 2005-10-21 | 2014-12-30 | Wake Forest University Health Sciences | Keratin bioceramic compositions |
US20070166348A1 (en) * | 2005-10-21 | 2007-07-19 | Van Dyke Mark E | Keratin bioceramic compositions |
US9968706B2 (en) | 2006-02-10 | 2018-05-15 | Wake Forest University Health Sciences | Nerve regeneration employing keratin biomaterials |
US20110137329A1 (en) * | 2006-02-10 | 2011-06-09 | Dyke Mark E Van | Nerve regeneration employing keratin biomaterials |
US8968764B2 (en) | 2006-02-10 | 2015-03-03 | Wake Forest University Health Sciences | Nerve regeneration employing keratin biomaterials |
US10821211B2 (en) | 2006-02-17 | 2020-11-03 | Wake Forest University Health Sciences | Coatings and biomedical implants formed from keratin biomaterials |
US20090004242A1 (en) * | 2006-02-17 | 2009-01-01 | Van Dyke Mark E | Coatings and Biomedical Implants Formed From Keratin Biomaterials |
US8299013B2 (en) | 2006-02-17 | 2012-10-30 | Wake Forest University Health Sciences | Clotting and healing compositions containing keratin biomaterials |
US8273702B2 (en) | 2006-02-17 | 2012-09-25 | Wake Forest University Health Sciences | Wound healing compositions containing keratin biomaterials |
US8258093B2 (en) | 2006-02-17 | 2012-09-04 | Wake Forest University Health Sciences | Wound healing compositions containing keratin biomaterials |
US9149566B2 (en) | 2006-02-17 | 2015-10-06 | Wake Forest University Health Sciences | Coatings and biomedical implants formed from keratin biomaterials |
US20110142910A1 (en) * | 2006-02-17 | 2011-06-16 | Van Dyke Mark E | Clotting and Healing Compositions Containing Keratin Biomaterials |
US9068162B2 (en) | 2007-08-17 | 2015-06-30 | Wake Forest University Health Sciences | Keratin biomaterials for cell culture and methods of use |
US10434213B2 (en) | 2010-03-05 | 2019-10-08 | Wake Forest University Health Sciences | Controlled delivery system |
US20110217356A1 (en) * | 2010-03-05 | 2011-09-08 | Van Dyke Mark E | Controlled delivery system |
US8545893B2 (en) | 2010-03-08 | 2013-10-01 | Wake Forest University Health Sciences | Keratin biomaterials for treatment of ischemia |
US20110217285A1 (en) * | 2010-03-08 | 2011-09-08 | Van Dyke Mark E | Keratin biomaterials for treatment of ischemia |
US9220754B2 (en) | 2010-11-17 | 2015-12-29 | Wake Forest University Health Sciences | Keratin compositions for treatment of bone deficiency or injury |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US960914A (en) | Pills for the treatment of diabetes mellitus. | |
US3108040A (en) | Antiulcer concentrate and process for preparing same | |
JP2005170837A (en) | Marine alga extract and saccharide hydrolase inhibitor containing the same | |
US2987399A (en) | Process of obtaining the proteinaceous feed material from mustard seed, rape seed and similar seeds | |
CN110663803A (en) | Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach | |
JP5064714B2 (en) | Anti-stress composition | |
DE3223150A1 (en) | AMINO ACID MIXTURES, METHOD FOR THE PRODUCTION THEREOF | |
JP3247620B2 (en) | A therapeutic and / or prophylactic agent comprising a marine mineral component | |
Agrawal | Studies on the physiology of digestion in Corophium volutator | |
JPH05238940A (en) | Fast-acting medicine having high absorption rate in vivo and its production | |
CN103251100B (en) | Maggot peptide beverage and production technology thereof | |
KR20200064736A (en) | Fermented Sea Cucumber Tea, and Method for Mmanufacturing the Same | |
Mitchell | Comparative physiological values of five carbohydrates, based on growth and fecal analysis | |
CN102342400A (en) | High-calcium xylitol | |
EP1796696B1 (en) | Compounds, compositions, formulations and process for preparation thereof and method of treatment and management of acidity and related disorders | |
DE60037197T2 (en) | USE OF FUNCTIONAL ORAL PREPARATIONS | |
JPH0543470A (en) | Alcoholic fat liver suppresser | |
Roaf | A contribution to the study of the digestive gland in Mollusca and decapod Crustacea | |
EP0637592B1 (en) | Processes of producing amylase inhibitors | |
DE2209833A1 (en) | METHOD OF MANUFACTURING AN AMYLASE INHIBITOR | |
CN106974290A (en) | A kind of health-preserving food for preventing and treating intractable oral cavity ulcer | |
DE2209832A1 (en) | METHOD OF MANUFACTURING SACCHARAS INHIBITORS | |
KR101840425B1 (en) | Preparation methods of edible sugar including mineral produced from the pith of sunflower stalks | |
CN110724595B (en) | Biological polysaccharide flocculant and preparation method and application thereof | |
Roberts | Collected contributions on digestion and diet |